Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance

Int J Biol Macromol. 2022 Dec 1;222(Pt A):1538-1550. doi: 10.1016/j.ijbiomac.2022.09.105. Epub 2022 Sep 22.

Abstract

The recently developed pathogenic virus, SARS-CoV-2, was found in the Hubei Province, China. Giving rise to a broad spectrum of symptoms, SARS-CoV-2 rapidly spread across the globe, causing multi-systemic and dangerous complications, with death in extreme cases. Thereby, the number of research cases increases every day on preventing infection and treating its resulting damage. Accumulating evidence suggests noncoding RNAs (ncRNAs) are necessary for modifying virus infection and antiviral immune reaction, along with biological processes regulating SARS-CoV-2 and subsequent disease states. Therefore, understanding these mechanisms might provide a further understanding of the pathogenesis and feasible therapy alternatives against SARS-CoV2. Consequently, the molecular biology of SARS-CoV-2, ncRNA's role in its infection, and various RNA therapy tactics against the virus have been presented in this review section.

Keywords: Non-coding RNA; SARS-CoV-2; Therapy.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19*
  • Humans
  • RNA, Untranslated / genetics
  • RNA, Viral / genetics
  • SARS-CoV-2* / genetics

Substances

  • RNA, Viral
  • Antiviral Agents
  • RNA, Untranslated